Delivery Order SPE2DB22D3301-SPE2DB25FZ0PY
- Not listed
- The Defense Logistics Agency (DLA) awarded a $24,814.95 delivery order to AmerisourceBergen Drug Corp for ProQuad vials on September 24, 2025, with an ultimate completion date of October 16, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement. The delivery order represents a child...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency valued at $1,654.33 for ProQuad vials. This competitively awarded, firm fixed-price contract has an ultimate completion date of September 5, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $8,437.20 by the Defense Logistics Agency on September 2, 2025, for the supply of ProQuad vials with a completion date of September 23, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the pharmaceutical distributor's Corporate Office division. The place of performance is AmerisourceBergen's headquarters in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.48, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a $52,272.03 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. ProQuad is a combination vaccine protecting against measles, mumps, rubella, and varicella, making...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order for ProQuad vials valued at $6,683.60 by the Defense Logistics Agency (DLA). The contract, awarded on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a firm fixed-price delivery order with no set-aside designation. This award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $8,059.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on May 2, 2025, with an ultimate completion date of May 23, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million through December 2026. The work will be performed in Conshohocken, Pennsylvania, where the contractor maintains...
- The Defense Logistics Agency awarded a $6,749.92 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with a completion date of September 30, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. ProQuad is a combination vaccine used for immunization against measles, mumps, rubella, and varicella, making this delivery critical for federal medical...
- The Defense Logistics Agency awarded a $6,115.45 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with performance in Conshohocken, Pennsylvania and a completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The prime vendor contract serves as a comprehensive global...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a $16,543.30 delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for ProQuad vials with a completion date of July 22, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The delivery order will be performed at the...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0PYDelivery Order
The Defense Logistics Agency awarded a $16,543.30 delivery order (Contract 4569422403) to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of September 26, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. ProQuad is a combination vaccine protecting against measles, mumps, rubella, and varicella, making this delivery order representative of the broad pharmaceutical and vaccine supply requirements across the Defense Health Agency and broader military healthcare enterprise. AmerisourceBergen's extensive federal contract portfolio demonstrates its capability to fulfill diverse medical supply needs through open competition, ranging from routine commodity orders to specialized pharmaceutical products. This delivery order reflects the company's established role in supporting DoD's global pharmaceutical supply chain and military medical readiness initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.5k | 9/5/25 |